European Heart Journal Advance Access originally published online on August 25, 2006
European Heart Journal 2006 27(18):2217-2223; doi:10.1093/eurheartj/ehl208
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation
1 Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Chieti 66030, Italy
2 Epidemiological Unit, ULSS 4, Alto Vicentino, Vicenza, Italy
3 Department of Cardiology, IRCCS Policlinico S. Matteo, Pavia, Italy
Received 23 May 2006; revised 14 July 2006; accepted 10 August 2006; online publish-ahead-of-print 25 August 2006.
* Corresponding author. Tel: +39 0872570300; fax: +39 0872570248. E-mail address: monte{at}negrisud.it
Aims To assess the use of antithrombotic treatment (ATT) after hospitalization with atrial fibrillation (AF) and the attributable effectiveness of ATT during follow-up.
Methods and results On the basis of record linkage of administrative registers, 1812 patients discharged with AF were identified and followed-up for major clinical events up to 1 year. Mean age was 79 years. After hospitalization, 56% of the patients received ATT: 29% anticoagulants, 22% antiplatelets (APs), and 5% both agents. Among patients without comorbidities, 63.0% were exposed to ATT. Several factors significantly influence the use of antithrombotic agents, including increasing age [odds ratio (OR) 0.93 (95% confidence interval (CI), 0.92–0.95)], chronic obstructive pulmonary disease [0.77 (0.59–1.00)], malignancy [0.57 (0.39–0.82)], and previous use of ATT [4.56 (3.67–5.67)]. A significantly lower mortality was observed in patients exposed to ATT [hazard ratio (HR) 0.36 (95% CI, 0.28–0.47)], both to anticoagulants [0.23 (0.15–0.35)] and to APs [0.66 (0.50–0.86)]. ATT was associated with the reduction of thrombo-embolic events [0.52 (0.25–1.07)]. Major bleeding did not contribute to increased morbidity. Subgroups analysis, propensity score (PS), and sensitivity analysis confirmed these results.
Conclusion Our data demonstrated that ATT was underused, also in patients without comorbidities. Exposure to ATT is associated with improved survival among elderly high-risk community patients hospitalized with AF.
Key Words: Epidemiology • Medical record linkage • Antithrombotic treatment • Atrial fibrillation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Meiltz, M. Zimmermann, P. Urban, A. Bloch, and on behalf of the Association of Cardiologists of t Atrial fibrillation management by practice cardiologists: a prospective survey on the adherence to guidelines in the real world Europace, June 1, 2008; 10(6): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zamorano and V. Canadas The combination of anticoagulant and anti-platelet therapy in patients with atrial fibrillation: a comment on the recent ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: reply Eur. Heart J., December 1, 2006; 27(23): 2909 - 2910. [Full Text] [PDF]
|
|